Part I: Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx & the Real Story Is Why Investors Now Believe Healthcare Orchestration Beats SaaS

The $160 million Series B that Forus (formerly Tandem) closed at a $1 billion valuation marks a strategic pivot in digital health financing. Backed by Thrive Capital, General Catalyst and a slate of top‑tier venture firms, the round isn’t betting on another point‑solution for prior authorizations. Instead, investors are targeting the invisible “routing layer” that connects clinicians, payers, pharmacies and manufacturers—a layer likened to a Visa‑style transaction network rather than a traditional SaaS dashboard.

Why does this layer matter now? Specialty therapies routinely command $60,000 to $3 million per patient, turning every referral, benefit check, or co‑pay enrollment into a high‑stakes transaction. Delays or errors can cost manufacturers a full prescription’s revenue and jeopardize patient outcomes. Consequently, manufacturers, providers and payers are aligned to pay premium prices for services that shave days off time‑to‑therapy, reduce staff overhead, and improve documentation quality. The economics have shifted from a friction‑tolerant environment to one where efficient transaction coordination directly impacts the bottom line.

The episode also explains why classic SaaS models stumble in this space. Healthcare workflows fragment continuously—payer rules, formulary changes, and evolving drug economics outpace static software roadmaps. Companies that survive, like CoverMyMeds or Change Healthcare, do so by embedding themselves in the transaction flow and adopting usage‑based or revenue‑share pricing. Forus’s network‑centric approach, which links manufacturers, providers, specialty pharmacies and hub services, positions it to capture the emerging value of healthcare orchestration, potentially reshaping the incumbent PBM and EHR landscape.